Can a new pill help a failing heart pump better?
NCT ID NCT07750873
First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This clinical trial is testing an experimental drug called CRD-4730 in people with heart failure with reduced ejection fraction (HFrEF), a condition where the heart's main pumping chamber is weak. The drug works by blocking a protein called CaMKII, which is thought to contribute to heart muscle damage. The study will compare three different doses of CRD-4730 against a placebo, given alongside standard heart failure medications, to see if it can improve heart function and reduce strain on the heart over 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- CRD-4730, an experimental drug that inhibits CaMKII, a protein involved in heart cell stress and dysfunction
- What this could lead to
- If successful, this could lead to a new treatment option for heart failure with reduced ejection fraction, potentially improving heart function and reducing symptoms.
- What could go wrong
- This is a phase 2 trial, so results are preliminary and may not translate to real-world benefit. The drug may cause side effects or fail to show significant improvement over placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 525 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2026
- Expected to finish
-
Sep 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult male or female patient ≥ 18 years of age and ≤ 85 years of age at the time of screening. * Has a medical history supporting a diagnosis of clinical chronic heart failure (HF) syndrome with a duration of at least 8 weeks prior to the time of screening and current NYHA functional class II to III (based on investigator's assessment). * Has left ventricular ejection fraction ≤ 40% by a centrally read transthoracic echocardiogram performed during screening. * Has NT-proBNP level ≥ 600 pg/mL (70.8 pmol/L) at the time of screening. Patients in atrial fibrillation or flutter at the time of screening are required to have an NT-proBNP level of ≥ 900 pg/mL (106.4 pmol/L). * Is receiving optimized and stable guideline directed HF therapy (per applicable regional or national guidelines). Exclusion Criteria: * Has evidence of recent HF exacerbation defined by hospitalization or requirement for IV or SQ diuretics within 4 weeks of the time of screening or during the Screening Period. * Has a requirement for routine, scheduled outpatient IV infusions for HF (ie, inotropes, vasodilators, or diuretics) or routinely scheduled ultrafiltration. * Has acute coronary syndrome, unstable angina, persistent angina at rest, stroke, transient ischemic attack, cardiac, carotid or other major cardiovascular surgery, cardiac valve repair (surgical or nonsurgical) or surgical replacement, or carotid angioplasty within 8 weeks prior to screening or during the Screening Period. * Has clinical suspicion of infiltrative cardiomyopathy (eg, amyloid, sarcoid), hypertrophic cardiomyopathy (obstructive or non-obstructive), or HF secondary to severe valvular disease, active myocarditis, active pericarditis, or clinically significant congenital heart disease. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Heart failure with reduced ejection fraction (hfref) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Cardurion Investigative Site
RECRUITINGPasadena, California, 91105, United States
-
Cardurion Investigative Site
RECRUITINGBloomfield Hills, Michigan, 48304, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Tiny heart shunt aims to keep heart failure patients out of the hospital
- Can a traditional chinese medicine injection ease heart failure symptoms?
- Can a valve fix unlock better heart failure drugs?
- Iron showdown: IV vs. pills for heart failure fatigue
- Heart failure drug aims to boost daily living and cut hospital visits
- New tool aims to help heart failure patients get the right meds